# Ebglyss (lebrikizumab-lbkz) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lebrikizumab-lbkz

> The FDA approved Ebglyss (lebrikizumab-lbkz), sponsored by ELI LILLY & Co (LLY), on September 13, 2024 for to treat moderate-to-severe atopic dermatitis.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Ebglyss (lebrikizumab-lbkz) FDA approved?

Yes. The FDA approved Ebglyss (lebrikizumab-lbkz), sponsored by ELI LILLY & Co (LLY), on September 13, 2024 for to treat moderate-to-severe atopic dermatitis. FDA novel drug approvals: "Ebglyss | lebrikizumab-lbkz | 9/13/2024 | To treat moderate-to-severe atopic dermatitisDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/lebrikizumab-lbkz)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/lebrikizumab-lbkz#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Ebglyss (lebrikizumab-lbkz) |
| Codes |  |
| Sponsor | ELI LILLY & Co (LLY) https://sec-api.dev/companies/lly/catalysts |
| Indications | To treat moderate-to-severe atopic dermatitis |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### September 28, 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22761306_2024_Orig1s000OtherActionLtrs.pdf%22

### September 13, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat moderate-to-severe atopic dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Ebglyss | lebrikizumab-lbkz | 9/13/2024 | To treat moderate-to-severe atopic dermatitisDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "BLA761306 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240913, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product EBGLYSS (LEBRIKIZUMAB-LBKZ)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761306%22

### June 9, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761306 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260609, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product EBGLYSS (LEBRIKIZUMAB-LBKZ)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761306%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lebrikizumab-lbkz.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ebglyss (lebrikizumab-lbkz) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lebrikizumab-lbkz

```bibtex
@misc{secapidev_pdufa_lebrikizumab_lbkz_20261116,
  title        = {Ebglyss (lebrikizumab-lbkz) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lebrikizumab-lbkz}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lebrikizumab_lbkz_20261116","title":"Ebglyss (lebrikizumab-lbkz) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lebrikizumab-lbkz","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
